Lenvatinib clinical trials
Also written Lenvima, E7080 and MK-7902.
ClinicalTrials.gov finds 696 studies for lenvatinib. How that becomes 431 here
Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives lenvatinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 696Found by its intervention search · See all 696 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 588 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −13
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein BindingNCT02998775 · Plasma for laboratory protein-binding tests; no one is given itReport a problem
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursNCT03468426 · Earlier treatment, not given in this studyReport a problem
- Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)NCT03499626 · Earlier treatment, not given in this studyReport a problem
- Study of Anlotinib After Lenvatinib in Patients With Hepatocellular CarcinomaNCT04080154 · Earlier treatment, not given in this studyReport a problem
- A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)NCT04605796 · The record's entry miswrites bevacizumab; lenvatinib is not givenReport a problem
- HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular CarcinamaNCT04627363 · The arm text is copied in error; bevacizumab is givenReport a problem
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaNCT04714697 · Earlier treatment, not given in this studyReport a problem
- Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.NCT05660954 · Earlier treatment, not given in this studyReport a problem
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCCNCT05831969 · Earlier treatment, not given in this studyReport a problem
- dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular CarcinomaNCT06609863 · The arm text is copied in error; bevacizumab is givenReport a problem
- Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular CarcinomaNCT06644430 · Named only as a keywordReport a problem
- Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep LearningNCT07417800 · Named only as a usual adjuvant drug in the backgroundReport a problem
- Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC TrialNCT07514429 · Earlier treatment, not given in this studyReport a problem
- −1New since the last reading, not read yet
- 682Give lenvatinib to participants
- −74Observe patients on it, or give it outside a trial
- −2Use it as a tool: an imaging tracer or a test of drug response
- −8Compare another treatment with it
- −167Give it beside what is tested
- 431Test it: the count on this site
Get an email when these change. Save the lenvatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Feb 2015 · LENVIMA · NDA 206947 (FDA, Drugs@FDA)
- European Union
- 28 May 2015 · Lenvima · EMEA/H/C/003727 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
430 studies that test it; most in 2021 (52); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 8 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 7 |
| 2016 | 12 |
| 2017 | 12 |
| 2018 | 21 |
| 2019 | 30 |
| 2020 | 37 |
| 2021 | 52 |
| 2022 | 51 |
| 2023 | 48 |
| 2024 | 43 |
| 2025 | 39 |
| 2026 | 49 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 81 · Other 350
Eisai Inc. (35) · Sun Yat-sen University (34) · Merck Sharp & Dohme LLC (26) · Tianjin Medical University Cancer Institute and Hospital (20) · Fudan University (19) · Shanghai Zhongshan Hospital (15) · Peking Union Medical College Hospital (14) · Eisai Co., Ltd. (12)
Often tested with
Tested in the same studies.
Pembrolizumab (97) · Tislelizumab (29) · Sintilimab (23) · Durvalumab (13) · Immune checkpoint inhibitors (13) · Toripalimab (12) · Iparomlimab/Tuvonralimab (10) · Nivolumab (8)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Lenvatinib is the comparator. A study of two new drugs counts under both.
- 1Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 · BeOne Medicines · next primary completion Sep 2029
New treatments tested with it · 8 most studied
New when their studies opened, with lenvatinib beside them; studies of each.
Reaching primary completion within a year · 62, 3 in phase 3
Studies that test lenvatinib, phase 3 first.
- Dec 2026Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaPhase 3 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- May 2027Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyPhase 3 · Shanghai Junshi Bioscience Co., Ltd.
- Jul 2027Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCPhase 3 · Sun Yat-sen University
- Nov 2026HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaNot applicable · Tianjin Medical University Cancer Institute and Hospital
- Nov 2026Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular CarcinomaPhase 2 · Asan Medical Center
- Nov 2026Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaPhase 2 · AstraZeneca
- Dec 2026Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract TumorsPhase 2 · Eastern Hepatobiliary Surgery Hospital
- Dec 2026Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor ThrombusPhase 2 · University of Texas Southwestern Medical Center
- Dec 2026Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaPhase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses lenvatinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 431
- Merck IIT: RRP Pembro and LenvatinibRecruitingPhase 2Yale UniversityNCT04645602With pembrolizumab in recurrent respiratory papillomatosisWritten as LenvatinibReport a problem
- First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentRecruitingPhase 2National Cancer Center, KoreaNCT07297654First-line in Child-Pugh B liver cancerWritten as LenvatinibReport a problem
- Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell CarcinomaNot yet recruitingPhase 2Vall d'Hebron Institute of OncologyNCT07593040With pembrolizumab before kidney cancer surgeryWritten as LenvatinbReport a problem
- QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma PatientsNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07933016Part of a new three-drug combination with QL1706 in liver cancerReport a problem
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingPhase 2Chen XiaopingNCT06420440With tislelizumab before surgery, against direct resectionWritten as LenvatinibReport a problem
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06253494Dose-finding beside a new HER2 vaccine in endometrial cancerWritten as LenvatinibReport a problem
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingPhase 1/2Asan Medical CenterNCT07149090With nivolumab and chemotherapy in gastric cancer with ascitesWritten as LenvatinibReport a problem
- PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingPhase 2Chang Gung Memorial HospitalNCT07827807With partial TACE in unresectable liver cancerWritten as LenvatinibReport a problem
- Prospective Study of Cadonilimab With Lenvatinib in Renal Cell CarcinomaRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07909265With cadonilimab in kidney cancerReport a problem
- Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07902648With serplulimab and DOS and PIPACReport a problem
- Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional ChemotherapyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07897565Modified dose with gemcitabine and toripalimab in older patientsReport a problem
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 3Zhejiang Cancer HospitalNCT07691515With tislelizumab and TACE against chemotherapy with tislelizumabWritten as LenvatinibReport a problem
- Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07894367With gematinib in MET-overexpressing lung cancerWritten as LenvatinibReport a problem
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingPhase 2Tongji HospitalNCT07417501With a PD-1 inhibitor in tumours with 11q13 amplificationWritten as Lenvatinib plus PD-1 InhibitorReport a problem
- Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07870772Added to bevacizumab and a PD-1 inhibitor after progressionReport a problem
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05064280With pembrolizumab in brain metastasesWritten as LenvatinibReport a problem
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07847359With iparomlimab/tuvonralimab and dacarbazine and cryoablationWritten as LenvatinibReport a problem
- Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingPhase 2Yonsei UniversityNCT07843901Single-arm in parathyroid carcinomaWritten as LenvatinibReport a problem
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingPhase 2University of MiamiNCT07594015With pembrolizumab in endometrial cancer after immunotherapyWritten as LenvatinibReport a problem
- Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingPhase 2Peking Union Medical College HospitalNCT07835893Added to chemotherapy in pancreatic neuroendocrine liver metastasesWritten as LenvatinibReport a problem
See all 431 studies that test lenvatinib →
Behind its US label · 6 — the studies the FDA label of LENVIMA describes
From the Clinical Studies section of LENVIMA (2026-06), as openFDA has it. A study the site does not hold is left out.
- A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted TreatmentCompletedPhase 1/2Eisai Inc.NCT01136733Report a problem
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)CompletedPhase 3Eisai Inc.NCT01321554Report a problem
- A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaCompletedPhase 3Eisai LimitedNCT01761266Report a problem
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingPhase 3Eisai Inc.NCT02811861Report a problem
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedPhase 3Eisai Inc.NCT03517449Report a problem
- Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedPhase 2Merck Sharp & Dohme LLCNCT04704219Report a problem
Tested on its own · 79 — no other medicine in its arm
- First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentRecruitingPhase 2National Cancer Center, KoreaNCT07297654First-line in Child-Pugh B liver cancerWritten as LenvatinibReport a problem
- Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant AscitesRecruitingPhase 1/2Asan Medical CenterNCT07149090With nivolumab and chemotherapy in gastric cancer with ascitesWritten as LenvatinibReport a problem
- PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingPhase 2Chang Gung Memorial HospitalNCT07827807With partial TACE in unresectable liver cancerWritten as LenvatinibReport a problem
- Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingPhase 2Yonsei UniversityNCT07843901Single-arm in parathyroid carcinomaWritten as LenvatinibReport a problem
- Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingPhase 2Peking Union Medical College HospitalNCT07835893Added to chemotherapy in pancreatic neuroendocrine liver metastasesWritten as LenvatinibReport a problem
- Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidineEnrolling by invitationPhase 1/2Seoul National University Bundang HospitalNCT07683949With capecitabine in refractory colorectal cancerWritten as Lenvanib (Lenvatinib),Xeloda (capecitabine)Report a problem
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNot applicableShanghai Zhongshan HospitalNCT06794073With tislelizumab, TACE and ablation in liver cancerReport a problem
- Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsRecruitingPhase 1/2Asan Medical CenterNCT07096609Single-arm after three prior drugs in GISTWritten as Lenvatinib CapsulesReport a problem
- Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)RecruitingPhase 2Washington University School of MedicineNCT0709251424 mg against 10 mg daily in thyroid cancerWritten as LenvatinibReport a problem
- Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06762782Adjuvant after surgery against monitoringWritten as Postoperative adjuvant lenvatinibReport a problem
- Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 4Zhiyong HuangNCT06417606With adebrelimab and GEMOX around surgeryWritten as LenvatinibReport a problem
- Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingEarly Phase 1Chang Gung Memorial HospitalNCT06327269Adjuvant after living donor liver transplantWritten as Lenvatinib 10 mgReport a problem
- Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNot applicableSun Yat-sen UniversityNCT05444478Added to microwave ablation for recurrent liver cancerWritten as LenvatinibReport a problem
- Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)RecruitingNot applicableLeiden University Medical CenterNCT04858867To restore radioiodine uptake in refractory thyroid cancerReport a problem
- Lenvatinib for Advanced Bone and Soft Tissue SarcomaRecruitingPhase 2Henan Cancer HospitalNCT05617859Single-arm after TKIs in bone and soft tissue sarcomaWritten as Lenvatinib mesylate capsuleReport a problem
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingPhase 2/3RenJi HospitalNCT04319484Lenvatinib against placebo after transplant with portal vein thrombusWritten as lenvatinibReport a problem
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsCompletedPhase 2The Methodist Hospital Research InstituteNCT05171335With TACE before liver transplantWritten as LenvatinibReport a problem
- Lenvatinib in Locally Advanced Invasive Thyroid CancerCompletedPhase 2Massachusetts Eye and Ear InfirmaryNCT04321954Before surgery in invasive thyroid cancerWritten as LENVATINIBReport a problem
- Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02780310Single-arm in adenoid cystic carcinomaWritten as LenvatinibReport a problem
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantTerminatedPhase 2Emory UniversityNCT05103904Single-arm for liver cancer recurring after transplantWritten as LenvatinibReport a problem
Showing 20 of 79. See all 79 →
Tested with established drugs · 43 — they are given beside it
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingPhase 2Chen XiaopingNCT06420440With tislelizumab before surgery, against direct resectionWritten as LenvatinibReport a problem
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 3Zhejiang Cancer HospitalNCT07691515With tislelizumab and TACE against chemotherapy with tislelizumabWritten as LenvatinibReport a problem
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06880523Added to durvalumab and tremelimumab in liver cancerWritten as LenvatinibReport a problem
- STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingPhase 2Dongguan People's HospitalNCT07754734Added to the Stupp regimen in glioblastomaWritten as LenvatinibReport a problem
- Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingPhase 1Aaron WolfsonNCT05603910Dose-finding with pembrolizumab and pelvic radiationWritten as LenvatinibReport a problem
- Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral MelanomaNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07501104With pucotenlimab and temozolomide in melanomaWritten as Neoadjuvant Pucotenlimab+Lenvatinib+TemozolomideReport a problem
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingPhase 2Changhai HospitalNCT07490002With QL1706 and chemotherapy in esophageal cancerWritten as Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxelReport a problem
- Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05532059With tislelizumab and chemotherapy in cholangiocarcinomaWritten as Lenvatinib, tislelizumab, gemcitabine and cisplatinReport a problem
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05823311With tislelizumab and chemotherapy in cholangiocarcinomaWritten as Lenvatinib, tislelizumab, gemcitabine and cisplatinReport a problem
- GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT05215665Added to GEMOX and toripalimab in cholangiocarcinomaWritten as LenvatinibReport a problem
- Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCRecruitingPhase 3Sun Yat-sen UniversityNCT06041477Concurrent against sequential with HAIC and a PD-1 antibodyReport a problem
- FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06409637Added to FOLFOX after liver transplantWritten as lenvatinibReport a problem
- Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingPhase 2Peking Union Medical College HospitalNCT06362317With toripalimab first-line in biliary cancerWritten as LenvatinibReport a problem
- Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albuminEnrolling by invitationPhase 2Fudan UniversityNCT06030934With envafolimab and nab-paclitaxel in gastric cancerWritten as envafolimab and lenvatinib combined with paclitaxel-albuminReport a problem
- Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingPhase 2Hyogo Medical UniversityNCT06318286Added to pembrolizumab and chemotherapy in mesotheliomaWritten as LenvatinibReport a problem
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedPhase 3Merck Sharp & Dohme LLCNCT04949256Added to pembrolizumab and chemotherapy in esophageal cancerWritten as LenvatinibReport a problem
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT05081180Dose-finding with avelumab in children's brain tumoursWritten as LenvatinibReport a problem
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT04199104Added to pembrolizumab in head and neck cancer, against placeboWritten as LenvatinibReport a problem
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedPhase 3Merck Sharp & Dohme LLCNCT05523323Added to pembrolizumab in head and neck cancer, against placeboWritten as LenvatinibReport a problem
- Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedPhase 3Merck Sharp & Dohme LLCNCT03829332Added to pembrolizumab in PD-L1 positive lung cancer, against placeboWritten as LenvatinibReport a problem
Showing 20 of 43. See all 43 →
Tested in a combination · 307 — another drug in the study is under test too
- Merck IIT: RRP Pembro and LenvatinibRecruitingPhase 2Yale UniversityNCT04645602With pembrolizumab in recurrent respiratory papillomatosisWritten as LenvatinibReport a problem
- Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell CarcinomaNot yet recruitingPhase 2Vall d'Hebron Institute of OncologyNCT07593040With pembrolizumab before kidney cancer surgeryWritten as LenvatinbReport a problem
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06253494Dose-finding beside a new HER2 vaccine in endometrial cancerWritten as LenvatinibReport a problem
- Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07902648With serplulimab and DOS and PIPACReport a problem
- Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional ChemotherapyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07897565Modified dose with gemcitabine and toripalimab in older patientsReport a problem
- Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07894367With gematinib in MET-overexpressing lung cancerWritten as LenvatinibReport a problem
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingPhase 2Tongji HospitalNCT07417501With a PD-1 inhibitor in tumours with 11q13 amplificationWritten as Lenvatinib plus PD-1 InhibitorReport a problem
- Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07870772Added to bevacizumab and a PD-1 inhibitor after progressionReport a problem
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05064280With pembrolizumab in brain metastasesWritten as LenvatinibReport a problem
- Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingPhase 2Sun Yat-sen UniversityNCT07847359With iparomlimab/tuvonralimab and dacarbazine and cryoablationWritten as LenvatinibReport a problem
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingPhase 2University of MiamiNCT07594015With pembrolizumab in endometrial cancer after immunotherapyWritten as LenvatinibReport a problem
- Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor ThrombusRecruitingPhase 2University of Texas Southwestern Medical CenterNCT05319015With pembrolizumab before surgery for kidney cancer thrombusWritten as Neoadjuvant LenvatinibReport a problem
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07776080With QL1706 and radiotherapy and HAICWritten as LenvatinibReport a problem
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingPhase 2Georgetown UniversityNCT04865887With pembrolizumab in advanced cervical cancerWritten as LenvatinibReport a problem
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingPhase 2Fudan UniversityNCT07256223With envafolimab in kidney cancer and liver spreadWritten as Envafolimab+LenvatinibReport a problem
- A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene TranslocationRecruitingPhase 3EuroCityClinic LLCNCT07809256With pembrolizumab in RET-rearranged lung cancerReport a problem
- Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCCRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07801287With iparomlimab/tuvonralimab and SBRTWritten as Iparomlimab/Tuvonralimab plus SBRT and LenvatinibReport a problem
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419A targeted option with HAIC and a PD-1 drug after liver surgeryWritten as Donafenib + lenvatinib+apatinibReport a problem
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingPhase 2Tongji HospitalNCT06187961With cadonilimab and HAICWritten as LenvatinibReport a problem
- Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT05733715Added to pembrolizumab around kidney cancer surgeryWritten as Lenvatinib tabletReport a problem
Showing 20 of 307. See all 307 →
Beside an established treatment under test · 55 — an approved drug, surgery or radiation is what the study tests
Tested with lenvatinib: Surgery or a procedure 21 · Radiation 13 · belzutifan 3 · Immune checkpoint inhibitors 3 · atezolizumab 2 · tislelizumab 2 · pembrolizumab 2 · Lenalidomide 1
- Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsRecruitingPhase 2Kidney Cancer Research BureauNCT07928167In every armBoth arms take it with pembrolizumab; radiotherapy is addedWritten as LenvatinibReport a problem
- Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07922928In every armBoth arms take it with toripalimab; radiotherapy is addedWritten as LenvatinibReport a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686In every armA standard option; radiation is added in kidney cancerWritten as LenvatinibReport a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07405164Continues beside belzutifan in an extension studyWritten as LenvatinibReport a problem
- Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT06841172One continued first-line option; radiotherapy is addedReport a problem
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07829926In every armBoth arms take it with tislelizumab; gefitinib is addedWritten as LenvatinibReport a problem
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingPhase 2Shunda DuNCT07832006In every armBoth arms take it with sintilimab; electroporation is addedWritten as LenvatinibReport a problem
- Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTTRecruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT06904183Both arms take it with sintilimab and DEB-TACE; HAIC is addedReport a problem
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingPhase 2Academic and Community Cancer Research UnitedNCT05168163In every armControl backbone with cabozantinib; atezolizumab is addedWritten as LenvatinibReport a problem
- Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersRecruitingPhase 2Peking UniversityNCT06580574Part of intensified therapy when a PD-1 antibody falls shortReport a problem
- Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver CancerNot yet recruitingPhase 3Tongji HospitalNCT07537946In every armEveryone takes it with sintilimab; local therapy is addedWritten as LenvatinibReport a problem
- Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular CarcinomaRecruitingNot applicableBangladesh Medical UniversityNCT07408804In every armBoth arms take it; TACE is addedWritten as LenvatinibReport a problem
- Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)RecruitingPhase 3Sun Yat-sen UniversityNCT06726421A standard option; SBRT is added in kidney cancerReport a problem
- An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingPhase 2Peking Union Medical College HospitalNCT07282262Partner of ivosidenib in IDH1-mutant biliary cancerWritten as LenvatinibReport a problem
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingPhase 2Peking Union Medical College HospitalNCT07157969In every armAn option in the systemic regimen; interventional therapy is addedWritten as LenvatinibReport a problem
- A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECISTNot yet recruitingNot applicableShanghai Zhongshan HospitalNCT07208526Part of the GOLP regimen; surgery timing is the questionReport a problem
- Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.RecruitingPhase 4Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06903312A standard option; tumour ablation is added in kidney cancerReport a problem
- Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingPhase 2Fudan UniversityNCT07047586In every armBoth arms take it; tislelizumab is addedWritten as LenvatinibReport a problem
- Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCCRecruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT06904196In every armBoth arms take it; SIRT is addedWritten as Lenvatinib plus SIRTReport a problem
- Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTTRecruitingPhase 3Second Affiliated Hospital of Guangzhou Medical UniversityNCT06492395Both arms take it with DEB-TACE; HAIC is addedReport a problem
Showing 20 of 55. See all 55 →
Beside a new treatment under test · 104 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with lenvatinib: Pembrolizumab/Quavonlimab MK-1308A 7 · Anti-ILT4 Monoclonal Antibody MK-4830 5 · cadonilimab 5 · favezelimab 5 · H-101 5 · belzutifan 4 · tislelizumab 4 · toripalimab 3
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Continues beside pembrolizumab in an extension studyWritten as LenvatinibReport a problem
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07933419Partner of new QLS5133 in some armsReport a problem
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingPhase 2CatalYm GmbHNCT07219459In every armBoth arms take it; new visugromab with nivolumab is addedWritten as LenvatinibReport a problem
- Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07922915In every armPartner of new pucotenlimab with radiotherapy before kidney surgeryWritten as LenvatinibReport a problem
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingPhase 2Sun Yat-sen UniversityNCT07487662Beside new ipilimumab N01 and sintilimab in some armsWritten as LenvatinibReport a problem
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingPhase 1/2GI Innovation, Inc.NCT04977453Partner option for new GI-101Written as LenvatinibReport a problem
- Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract CancerRecruitingPhase 2Peking Union Medical College HospitalNCT07159204Partner of micellar paclitaxel in biliary cancerReport a problem
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07874321In every armOngoing treatment; new MRG003 is addedWritten as LenvatinibReport a problem
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT05319730Partner of new MK-4830 with pembrolizumabWritten as LenvatinibReport a problem
- A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard TherapyRecruitingPhase 1ImmuneOncia Therapeutics Inc.NCT05276310Partner of new IMC-002 in a liver cancer cohortReport a problem
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Not yet recruitingPhase 2Fudan UniversityNCT07829874In every armPartner of QL1706 with or without cryoablationWritten as LenvatinibReport a problem
- A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCCNot yet recruitingPhase 1/2Zhejiang Haichang Biotech Co., Ltd.NCT07540832In every armBoth arms take it; WGI-0301 is addedWritten as LenvatinbReport a problem
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingPhase 1/2Michael J. Dennis, MDNCT05774899Partner of new CB-103 in adenoid cystic carcinomaWritten as LenvatinibReport a problem
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-ImmunotherapyRecruitingPhase 2Wang XinNCT07463248One first-line TKI continued; PULSAR and FMT are addedReport a problem
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Partner option for new LM-2417Written as LenvatinibReport a problem
- Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07686926In every armPartner of new becotatug vedotin with tislelizumabWritten as LenvatinibReport a problem
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingPhase 2Peking Union Medical College HospitalNCT07704177In every armPartner of new trastuzumab rezetecan and adebrelimabWritten as LenvatinibReport a problem
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingPhase 2Peking Union Medical College HospitalNCT07670273In every armPartner of new trastuzumab rezetecan and adebrelimabWritten as LenvatinibReport a problem
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT07383441In every armA standard option; live biotherapy is added in kidney cancerWritten as LenvatinibReport a problem
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06986785In every armPartner of new BL-B01D1Written as LenvatinibReport a problem
Showing 20 of 104. See all 104 →
Beside supportive care · 2 — a supportive treatment or test is studied
- The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesRecruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07381634A standard liver cancer option; ondansetron is tested for toxicityReport a problem
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.CompletedPhase 2Fudan UniversityNCT05673824One TKI option; Huaier granule is tested for kidney effectsReport a problem
One option of several · 5 — a test or a strategy chooses among drugs
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Optional partner of vebecotutamab in one salivary cohortReport a problem
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2Eastern Hepatobiliary Surgery HospitalNCT07351513One option chosen by organoid testingReport a problem
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract CancersNot yet recruitingPhase 2Eastern Hepatobiliary Surgery HospitalNCT07351591One option chosen by organoid testingReport a problem
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086In every armOne of the drugs chosen by organoid testingWritten as LenvatinibReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs in individualised combinationsWritten as LenvatinibReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 8 — what is tested is compared with lenvatinib
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaRecruitingPhase 3BeOne MedicinesNCT07836530An investigator's-choice control against new BGB-B2033Written as LenvatinibReport a problem
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)RecruitingPhase 1AbbVieNCT06858813The comparator for new ABBV-324Written as LenvatinibReport a problem
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingPhase 2Fudan UniversityNCT07328009The control and backbone in a liver cancer platform trialWritten as LenvatinibReport a problem
- Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCCRecruitingPhase 3Second Affiliated Hospital of Guangzhou Medical UniversityNCT05985798The comparator with TACE for sintilimab, bevacizumab and TACEReport a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607One control option against nivolumab plus ipilimumabWritten as lenvatinibReport a problem
- CXD101 in Immunotherapy-related Liver CancerActive, not recruitingPhase 2Stephen Chan LamNCT05873244A control option against new CXD101 with geptanolimabWritten as Lenvatinib and SorafenibReport a problem
- Immunotherapy for Advanced Liver CancerSuspendedPhase 2/3Mirror Biologics, Inc.NCT05033522One physician's-choice option against AlloStimWritten as LenvatinibReport a problem
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752The standard control against new livmoniplimabWritten as LenvatinibReport a problem
Observed · 74 — patients on it are followed, or it is given outside a trial
- Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter StudyNot yet recruitingIRCCS San RaffaeleNCT07927764Long-term survival on lenvatinib in thyroid cancer, in practiceReport a problem
- TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)Not yet recruitingZhongda HospitalNCT07836309Observes it with tislelizumab and TACEReport a problem
- Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus PembrolizumabRecruitingCHA UniversityNCT06648057Biomarkers in biliary cancer on lenvatinib with pembrolizumabWritten as lenvatinib plus pembrolizumabReport a problem
- Response to Neoadjuvant Treatment in Locally Advanced Thyroid CancerRecruitingFujian Medical UniversityNCT07419932One multikinase option before thyroid surgeryWritten as Multitarget Tyrosine Kinase InhibitorsReport a problem
- TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular CarcinomaNot yet recruitingTongji HospitalNCT07340502Observes TACE against HAIC with it and PD-1 drugsWritten as LenvatinibReport a problem
- International Multicentric Study ARON-1RecruitingHospital of MacerataNCT05287464One real-world combination in a kidney cancer registryReport a problem
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world DataNot yet recruitingXuhua DuanNCT07156617One targeted option with interventional therapyReport a problem
- Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal HypertensionRecruitingZhiyong HuangNCT06280313Observes it with immunotherapy after splenectomyReport a problem
- The Efficacy of Sequential RT After Triple Therapy for uHCCEnrolling by invitationFujian Provincial HospitalNCT07052448Observes radiotherapy after it with TACE and anti-PD-1Report a problem
- D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICCRecruitingFujian Provincial HospitalNCT06643208Observes it with D-TACE-HAIC and envafolimabReport a problem
- A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingFudan UniversityNCT05660213One registry cohort in stage III liver cancerReport a problem
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingZe-yang Ding, MDNCT05713994One cohort with HAIC and ICIsWritten as LenvatinibReport a problem
- HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular CarcinomaRecruitingSun Yat-sen UniversityNCT06333561Observes it with HAIC and PD-1 drugsWritten as LenvatinibReport a problem
- Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)Not yet recruitingFujian Provincial HospitalNCT06643533Observes FMT in resistance to triple therapy with itReport a problem
- Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingFujian Provincial HospitalNCT06602011Real-world triple therapy with TACE and tislelizumabWritten as TACE, Lenvatinib, combined with Tislelizumab groupReport a problem
- Neoadjuvant Triple Therapy for Resectable HCCRecruitingFujian Provincial HospitalNCT06569498Observes it with TACE and cadonilimab before surgeryReport a problem
- HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLCRecruitingFirst Hospital of China Medical UniversityNCT06632093Observes it with HAIC and PD-1 inhibitorsReport a problem
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)RecruitingFujian Provincial HospitalNCT06561399Observes it with TACE and sintilimab before radiotherapyReport a problem
- GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICCRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06505486Observes it with HAIC, gemcitabine and a PD-1 inhibitorReport a problem
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular CarcinomaRecruitingTongji HospitalNCT05717738One cohort with TACE and ICIsWritten as LenvatinibReport a problem
Showing 20 of 74. See all 74 →
As a tool · 2 — an imaging tracer or a test of drug response
- Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingPhase 1Oliver JonasNCT05700461A microdose in an implanted drug-screening deviceReport a problem
- Drug Screening Using Novel IMD in Salivary and Head and Neck CancersRecruitingEarly Phase 1Brigham and Women's HospitalNCT05553782A microdose in an implanted drug-screening deviceReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative TreatmentNov 16, 2026NCT07297654
Results posted1
Newly registered5
- QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma PatientsNov 12, 2026NCT07933016
- Prospective Study of Cadonilimab With Lenvatinib in Renal Cell CarcinomaNov 2, 2026NCT07909265
- Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaOct 29, 2026NCT07902648
- Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional ChemotherapyOct 27, 2026NCT07897565
- Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyOct 26, 2026NCT07894367
Codes
What other systems call lenvatinib · ClinicalTrials.gg INT005329
- MeSH (NLM) C531958lenvatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) EE083865G2LENVATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1603296Confirmed FDA, Wikidata
- Wikidata Q6523413lenvatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95124LenvatinibOne source FDA
- DrugBank DB09078One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531958 | lenvatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | EE083865G2 | LENVATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1603296 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6523413 | lenvatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95124 | Lenvatinib | One source FDA |
| DrugBank | DB09078 | — | One source Wikidata |
Also registered as 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide (UNII 269N24780P) and lenvatinib mesylate (UNII 3J78384F61 · RxNorm 1604346).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.